Direct-to-participant study to reach 150 people living with ALS, with 2 participants already enrolled. NEW YORK, Sept. 26, 2024 /PRNewswire/ -- In a first-of-a-kind collaboration, Target ALS, a ...
TherML™ integrates CombinAbleAI’s advanced, next generation biologics expertise with insitro’s existing small molecule and oligonucleotide capabilities, unifying therapeutic design across all major ...
insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML™ (Therapeutic Machine Learning) platform. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results